Merck & Co. (MRK) Q1 2024 Annual Earnings
MRK·Reported April 25, 2024·Before market open
Merck & Co. reported Q1 2024 revenue of $15.8B, beat analyst consensus of $15.2B by $569.9M. Diluted EPS came in at $2.07, beat the $1.88 consensus by $0.19. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Revenue
$15.8Bbeat by $569.9M
Consensus: $15.2BDiluted EPS
$2.07beat by $0.19
Consensus: $1.88
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Merck & Co.'s Q1 2024 earnings report.
Merck & Co. (MRK) reported Q1 2024 earnings on April 25, 2024 before market open.
Merck & Co. reported revenue of $15.8B and diluted EPS of $2.07 for Q1 2024.
Revenue beat the consensus estimate of $15.2B by $569.9M. EPS beat the consensus estimate of $1.88 by $0.19.
You can read the 10-K/A periodic report (0001193125-24-093194) directly on SEC EDGAR. The filing index links above go to sec.gov.